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Abstract. The review highlights the main features of internal audit by focus on distribution of 
medicinal products. Recent data suggest internal audit as an antidote to effects of economic recession. 
The present review reveals internal audit as a tool for competitiveness through implementation of good 
practices. 
The purpose of the review is to describe the advantages of internal audit in new institutional frame. 
The object of analysis is the distribution practice, and more concrete, the wholesale distributors. The 
analysis was perform by factor analysis and done in response to the tendency for outsource of distribution 
activities and practical interest in the use of internal audit by implementation of requirements and 
recommendations for good practices.  
The results showed that the internal audit in pharmaceutical industry is determinate by two factors: 
regulatory requirements and complexity of supply chain. The external and the internal environment define 
five features of internal audit in pharmaceutical industry. 
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Introduction 
Internal auditing is an independent, objective assurance and consulting activity designed to 
add value and improve an organization's operations [1]. According to regional legislations, the 
internal audit is defined for EU members as “self-inspection” [2] and as “measurement, analysis and 
improvement” according to ISO 9000:2000 [3]. The process of internal audit is carrying out by a 
distributor on its own systems, procedures and facilities [4]. The distributor employs the internal 
auditor.  
The reason for providing of internal audit is either legislation requirements or decision by 
management. The legislation requirements are based on standards described in ISO and good 
practices. The management must define audit agenda on fixed time or extraordinary. The target of 
audit activity should be verification of quality system and compliance with laws and regulations. 
The business benefits for the distributor are benchmarking and recommendations for corrective 
measures to achieve their stated objectives.  
At micro level, internal audit is organized depend on the size, structure and complexity of 
distributor’s organisation and activities. At macro level, there are different standards and regulations 
against which the distributor to be assessed.  
 
Distribution is an important part in supply chain of medicinal products [5]. The purpose 
of internal audit is compliance with requirements at every level. The complexity of supply 
process with medicinal products contains various stages with its own good practices: 
- at development stage complying with Good Clinical Practice [6] and Good Laboratory 
Practice [7]; 
- at manufacturing stage – Good Manufacturing Practices (GMP) [8]; 
- at distribution stage – Good Distribution Practice (GDP) [9]. 
In supply chain, the distributors shall carry on self-inspections for compliance with GDP 
while the competent authorities inspect distributors for compliance with GMP [10]. Regardless of 
the competent authority and time of accepting, every good practice provides existence of 
internal audit as managerial tool for safety, quality and efficacy of medicinal products. 
 
World Health Organization (WHO) introduced the first version of GMP in 1967. Based 
on WHO guidelines many countries (EU, US) and organizations (International Standard 
Organization, International Conference on Harmonization) developed their own guidelines 
[11]. GMP standards were harmonized in EU since 1991 and at supranational level 
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(International Conference on Harmonization is a common project of EU, US and Japan) since 
1999. 
 
GMP is mandatory for introduction for the manufacturers of medicinal products, but the 
addition of ISO 9001 to the already established GMP-system creates a better management of 
the system and provides additional benefits. The ISO standards represent an international 
consensus on good management practices instead of mandatory requirements by EU 
Directives. In EU, the ISO standards have been transposed as national standards by the national 
standards institutes, which are members of the European standardization bodies (CEN and 
CENELEC). The EU standards (EN ISO) are referred to some specific harmonization 
Directives. 
The ISO standards play an important role in the European Union’s industrial policy, both 
in relation to the promotion of the competitiveness of European industry, and with regard to the 
free movement of goods [12]. Adoption of ISO’s good practices in EU aims to comply with 
customers who require ISO certificate; to improve competiveness; to minimize repetitive 
auditing by similar and different customers, and to improve subcontractors’ performance. 
The additional advantage for manufacturers to adopt ISO 9001 is a management 
advantage over those who had not adopted the international quality management standard [13]. 
The introduction of ISO 9001 is a benefit to GMP by measurement of customer satisfaction. 
Simultaneous introduction of ISO 9001 and GMP is a benefit for lowest manufacturing 
expenditures.  
 
The distribution of medicinal products in Bulgaria is regulated by national legislation 
(Laws and Regulations) [14]. In addition, relevant EU documents (Directives, Regulations, and 
Guidelines) are also applicable. For import from non-EU countries, the wholesaling companies 
should comply with WHO Good Distribution Practice for pharmaceutical products. 
The GMP is described as a shared responsibility for quality, safety and efficacy of 
medical products (Regulation № 15 of 17.04.2009). The base of Bulgarian practice is the 
principles of EU GMP. The self-inspection is manufacture/importer responsibility for 
periodical control over implementation of GMP. 
The GDP is stated as a part of the quality system (Regulation No. 39 of 13 September 
2007 on the Rules and Requirements for the Good Distribution Practice by Ministry of Health). 
The base of GDP is a shared responsibility of quality and safety of the medicines.  
 
Materials and Methods  
The object of study is internal audit in wholesale distributors of medicinal products. The 
paper aims to review the existing good practices on the application of internal audit especially to 
improve quality control and to competitive power. We have used official sources - recommendations 
by international organizations, EU Directives for common policies and requirements by national 
legislation. The data analysis shows that the good manufacturing practice is an international matter 
while the good distribution practices – pan-European and national matter. 
 
Results 
By using of the factor analysis, we reveal two main factors for internal audit features: industry 
characteristics and distributor’s organization.  
 
The role of pharmaceutical industry defines the features of internal audit 
The features of internal audit are influence by growth opportunities due to advances in 
technology, the expansion of communication capabilities and the increasing complexity and 
sophistication of global business operations [15]. The current economic recession puts internal audit 
in agenda in pharmaceutical industry for competitive power and economic growth. The recession 
increases expenditures for internal audit activities and decreases expenditures for analysis. 
3 
 
The key role of pharmaceutical industry for society and national economy leads to 
requirements at every stage in the supply chain. From microeconomics point of view, the 
pharmaceutical industry is main element for the public health and needs of innovative and safety 
medicinal products on acceptable prices [16]. From macroeconomics point of view, the 
pharmaceutical industry is a strategic pillar for economic growth, employment and competitiveness.  
The complexity of pharmaceutical industry is higher than in rest industries due to overseas 
distribution and outsourcing of activities. The characters of the industry define the features of his 
internal audit: compliance with legislation, public health and safety, transparent procedures for 
pricing and reimbursement, intellectual property rights.  
The characteristics of industry are relevant to features of internal audit practices. The stronger 
requirements by regulator for some industries lead to increasing of investment in internal audit. 
Social important industries, such as financial and utilities are highly regulated [17]. Additionally, 
the pharmaceutical industry is highly regulated also and as distinguished from other industries, the 
regulators are from different industries and different legislations [18].  
 
The size and complexity of the distributor define the features of internal audit 
The size and structure of the distributor reflect on quality system and internal audit activities. 
Large distributors are more vulnerable to institutional pressures due to their prominent role in 
society [19]. The complexity of organization defines broader scope and larger staff for internal audit 
activities. The raising the standard of ISO 9001 requirements add high costs for small and medium 
sized enterprises to implement the new version and cancel out the added value they may derive 
from it [20]. 
 
Discussion  
Regulatory requirements for compliance with legislation, market pressure for implementation 
of guidelines for GDP and managerial expectations for corrective measures define the following 
features of internal audit in pharmaceutical industry: 
- Independence and objectivity. The internal audit shall be separate from other functions and 
activities of the distributor. The internal audit activities are independent of management and without 
undue influence. The independence is limit to the manager, whose sphere of authority it may audit 
and from the activities subject to audit. The internal auditor should report to the board and propose 
necessary corrective measures. The internal audit department must have sufficient financial 
resources and staff with the necessary skills to achieve monitoring for implementation and 
compliance with GDP. 
Directive 2003/94/EC laying down the principles and guidelines of GMP in respect of 
medicinal products for human use and investigational medicinal products for human use. The 
self-inspection is a part of quality assurance system in order to monitor the implementation and 
respect of good manufacturing practice and to propose any necessary corrective measures. 
GDP is described in Directive 2001/83/EC, Directive 2004/27/EC, and EU Guidelines on 
Good Distribution Practice of Medicinal Products for Human Use (2013/C 343/01). The aim of 
self-inspection is ensuring of maintaining the level of quality determined by throughout the 
distribution network.  
- Scope and frequency. The internal audit covers all aspects of GDP.  
The scope and frequency of the audit shall be clearly defined in an audit programme. The 
annual audit programme, approved by the board and external auditor, contains both fixed time and 
extraordinary inspections. Each business unit, supplier and subcontractor should be inspected once 
during the year. The minimum frequency for inspection is at least annually. 
The scope of internal audit within a defined period is compliance with regulations, guidelines 
and operating procedures. The internal audit process for complex distributors may be divided into 
several individual processes with limited scope. For example, in details - “internal audit of overseas 
warehouses”, or in general - “assessment of contract for transportation”.  
The scope of extraordinary audit is limited both for activities and for products. The 
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extraordinary audit should be carry on in case of complaints, returns, suspected falsified medicinal 
products recalls. 
- Approach. The internal audit activity evaluates and improves the effectiveness of processes 
by a systematic and disciplined approach. The audit manager designs the approach from clearly 
established objectives, scope and criteria. The internal audit role for determining the mistakes 
qualify the proactive approach as most using approach. The independence, focusing on details and 
broad scope are characteristics of internal audit due to complexity of pharmaceutical industry. In 
case of complex supply chain, the distributor carry on audit by principles of shared responsibility 
approach for safety and quality medicinal products [21]. 
- Staff. Internal audit is carrying out from experts nominated by the management under 
requirements of ISO 9001: 2008 Quality management systems (6.2). The organization shall 
issue and maintain documented procedures for Internal Audits (8.2.2). The standard uses an 
approach for effective issues, rather than execution of formally prescribed issues. The guidance 
on auditing management systems is provided by ISO 19011: 2011. 
The internal auditor is a part of company management and paid by the distributor. For small 
and medium distributors is recommended to hire an internal auditor outside the staff. The external 
auditor may not be used as a substitute for internal auditor. 
The internal audit should be conducted by designated competent person from the company 
who is indirectly involved and without charges to inspected object. The competency includes broad 
study fields, universality, and professional ethics. There are not requirements for knowledge, 
education and experience in pharmaceutical fields.  
- Administrative procedures. The volume of documentation is determined by the scope of 
inspection. Distributors’ organization for documents processing constitutes an essential part of the 
quality management system.  
All inspection results should be recorded [22]. The record should contain the observations and 
proposals for corrective measures, where applicable. The report should be provided to the board and 
be retained for a period not shorter than 5 years [23].  
The board should evaluate the inspection report and taken corrective actions, if any. Where 
necessary, shall be taken corrective action, including a follow-up audit of deficiencies [24]. The 
corrective and preventive action should be carry on with the principles of quality risk management.  
 
Conclusion 
Our results suggest that the features of internal audit are defined both by characteristics of the 
industry and the distributor. The key role and complexity of pharmaceutical industry lead to high 
expectations for internal audit activities. The size and structure of the distributor reflect on internal 
audit activities. 
Further study on internal audit is needed to reach the better conclusion. A comparative 
analysis by interviews with board members to reveal legislation requirements and managerial 
practices is highly recommended. 
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